Acrux Limited
Acrux Limited
Your view on ACR.AX
Overview
What the company does, where it operates, and who runs it.
About Acrux Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John Warmbrunn
- Headquarters
- 103-113, Stanley Street, West Melbourne, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John Warmbrunn
- Headquarters
- 103-113, Stanley Street, West Melbourne, VIC, AU
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets.
The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels.
Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Acrux Limited. Starting points for Acrux Limited: beta 0.99 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Acrux Limited. Acrux Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Acrux Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterJun 2017 | Next quarterJun 2018 | This yearYear to Jun 2017 | Next yearYear to Jun 2018 |
|---|---|---|---|---|
| Average estimate | AUD 0.03 | −AUD 0.06 | AUD 0.07 | AUD 0.09 |
| Lowest estimate | AUD 0.02 | −AUD 0.06 | AUD 0.07 | AUD 0.09 |
| Highest estimate | AUD 0.04 | −AUD 0.06 | AUD 0.07 | AUD 0.09 |
| Number of analysts | 3 | 3 | 3 | 2 |
| A year ago | — | — | — | — |
| Growth vs a year ago | — | — | — | — |
Revenue estimates
| Total | This quarterJun 2017 | Next quarterJun 2018 | This yearYear to Jun 2017 | Next yearYear to Jun 2018 |
|---|---|---|---|---|
| Average estimate | AUD 19.95M | AUD 2.93M | AUD 24.00M | AUD 28.63M |
| Lowest estimate | AUD 16.49M | AUD 2.69M | AUD 24.00M | AUD 28.63M |
| Highest estimate | AUD 22.76M | AUD 3.06M | AUD 24.00M | AUD 28.63M |
| Number of analysts | 3 | 3 | 4 | 3 |
| A year ago | — | — | — | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Acrux Limited. Acrux Limited has reported as a listed company since 2004. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| 1AD.AXAdAlta Limited | Healthcare | Biotechnology | — | ||
| ANR.AXAnatara Lifesciences Ltd | Healthcare | Biotechnology | — | ||
| BGT.AXBio-Gene Technology Limited | Basic Materials | Agricultural Inputs | — | ||
| BIT.AXBiotron Limited | Healthcare | Biotechnology | — | ||
| GLH.AXGlobal Health Limited | Healthcare | Medical - Care Facilities | — | ||
| HIQ.AXHITIQ Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| IBX.AXImagion Biosystems Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| IVX.AXInvion Limited | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PLRXPliant Therapeutics, Inc. | Healthcare | NASDAQ | $41.0M | ||
| PLRZPolyrizon Ltd. | Healthcare | NASDAQ | $12.4M | ||
| PLURPluri Inc. | Healthcare | NASDAQ | $9.9M | ||
| PLXProtalix BioTherapeutics, Inc. | Healthcare | AMEX | $254.6M | ||
| PLYXPolaryx Therapeutics, Inc. Common Stock | Healthcare | NASDAQ | $80.3M | ||
| PMCBPharmaCyte Biotech, Inc. | Healthcare | NASDAQ | $3.0M | ||
| PMNProMIS Neurosciences, Inc. | Healthcare | NASDAQ | $28.2M | ||
| PMVPPMV Pharmaceuticals, Inc. | Healthcare | NASDAQ | $65.1M | ||
| POLBFPoolbeg Pharma PLC | Healthcare | OTC | $46.6M | ||
| PPBTPurple Biotech Ltd. | Healthcare | NASDAQ | $236,124 | ||
| PPCBPropanc Biopharma Inc. Common Stock | Healthcare | NASDAQ | $1.8M | ||
| PPTDFPeptiDream Inc. | Healthcare | OTC | $1.1B | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Acrux Limited.